Please be advised that the Product Review Committee will be taking a break for two weeks. Specifically, there will be no product approval/review process from December 23, 2024 to January 3, 2025 inclusively for the following products:
- Exchange traded funds (ETF)
- Liquid alternative funds
- Exempt market products